返回
Structure Therapeutics Inc（GPCR）价格
GPCR 股价走势图
GPCR 收益
Structure Therapeutics Inc
$91.02
2.68%
$2.37
收盘价：Jan 20, 16:00:00 GMT-5
$93.76
3.01%
$2.74
盘后：Jan 20, 20:00:00 GMT-5
关键数据
前收盘价
$88.64
开盘价
$87.75
当日区间
$86.75 - $94.7
52周范围
$13.22 - $94.9
交易量
1.7M
平均成交量
1.5M
每股收益（TTM）
-1.22
股息收益率
--
市值
$5.6B
什么是 GPCR？
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California and currently employs 218 full-time employees. The company went IPO on 2023-02-03. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. The company is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. The company is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.